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a b s t r a c t
Introduction: Acute coronary syndrome encompasses acute forms of ischemic heart disease –
unstable angina and myocardial infarction with or without ST elevation. Chest pain patients
have a wide spectrum of cardiac risk including those with typical symptoms and abnormal
electrocardiography who require immediate catheter angiography with a view to interven-
tion; at the other end of the spectrum are those of low risk with atypical symptoms and a
normal ECG who can be discharged without investigation. Between these two groups is a
large number of patients with diagnostic uncertainty.
Methods: Radionuclide imaging can be useful in different phases of the course of athero-
sclerosis with subsequent myocardial ischemia. Primarily, radionuclide imaging can be used
for the identiﬁcation of subclinical coronary artery atherosclerosis to enhance primary
prevention of CAD, acute myocardial infarction, and sudden cardiac death. Secondly it
can be used at the emergency department to help to decide whether to admit or discharge a
patient presenting with chest pain. And ﬁnally it helps to stratify and follow patients who
survive ACS for choosing optimal treatment strategy.
Results: Radionuclide imaging is potentially able to detect endothelial dysfunction and early,
preclinical atherosclerotic plaques vulnerable to rupture. Rest 99mTc-sestamibi SPECT has
been shown to improve medical decision making by decreasing unnecessary hospitaliza-
tions. The strength of resting MPI lies with its high negative predictive value, approaching
100%. A possible future approach for risk stratiﬁcation of patients with suspected ACS
involves imaging myocardial fatty acid metabolism. The study of myocardial perfusion and
metabolism in the sub-acute phase of STEMI has allowed us to considerably improve our
knowledge of its pathophysiology, but its clinical usefulness is limited by the complex
interplay between epicardial artery obstruction, coronary microvascular obstruction, and
inﬂammatory cell activation.
Conclusion: The optimal imaging strategy in acute coronary syndromes is determined not
only by the diagnostic performance of a modality but also by local practice, expertise with
imaging techniques, medical facilities, and individual patient characteristics.
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The entity acute coronary syndrome (ACS) encompasses acute
forms of ischemic heart disease (IHD) – unstable angina and
myocardial infarction (MI) with or without ST elevation [1].
Patients with ACS frequently present with acute chest pain
complaints. Chest pain may be cardiac related or may be due to
non-cardiac causes such as musculoskeletal or gastrointesti-
nal pain; thus, acute chest pain is a common diagnostic
dilemma in the emergency department and its impact on the
health care system is substantial. It is important to identify
those patients with ischemic heart disease presenting with
chest pain [2]. Chest pain patients have a wide spectrum of
cardiac risk including those with typical symptoms and
abnormal electrocardiography (ECG) who require immediate
catheter angiography with a view to intervention; at the other
end of the spectrum are those of low risk with atypical
symptoms and a normal ECG who can be discharged without
investigation. Unfortunately, between these two groups is a
large number of patients with diagnostic uncertainty [3]. The
results of a large multicenter study showed that although most
patients (>60%) with suspected ACS were hospitalized for
further evaluation, only 17–20% were ultimately diagnosed
with ACS. Despite this conservative approach, a small
proportion of patients (0.4–10%) with ACS are misdiagnosed
and discharged without appropriate intervention with double
the risk-adjusted mortality of admitted patients [1,3–6].
Patients with ACS who are mistakenly discharged from the
emergency department generally have a worse prognosis than
appropriately managed patients, partly not only because of
their risk for sudden cardiac death, but also because of the
delay in implementing treatments that are known to be
beneﬁcial for ACS [1].
Coronary artery disease (CAD) is the development of
cholesterol-rich plaques within the walls of coronary arteries
(atherosclerosis). At any stage in the development of athero-
sclerosis, and often when the coronary artery lumen is
narrowed only slightly or not at all, an unstable plaque may
develop a tear of its inner lining cell layer, exposing the
underlying cholesterol-rich atheroma to the vessel lumen.
This atheroma is extremely thrombogenic and initiates
platelet aggregation and thrombus formation. Clinical conse-
quence of such a situation is ACS. Depending on the degree of
occlusion of the vessel lumen, time duration of the thrombus
(spontaneous thrombolysis), collateralization from other
vessels and conditioning of the myocardium to ischemia cell
death with subsequent necrosis can or cannot occur [3].Patients with ACS can die, can develop congestive heart failure
or can survive without clinical impairment depending on the
extent of myocardial necrosis.
Another important consideration is the presence of
coincidental CAD. The prevalence of asymptomatic non-
obstructive CAD is high, especially in the elderly population.
This disease may not be the cause of the patient's pain and
it is important not to ascribe the pain to being cardiac just
because of the presence of CAD. Conﬁrmatory evidence
must be sought so as to not ‘‘convert’’ an individual with
non-cardiac chest pain and coincidental CAD into a cardiac
patient [3].
Radionuclide imaging can be useful in different phases of
the course of atherosclerosis with subsequent myocardial
ischemia. I would like to divide its use into three groups.
Primarily, radionuclide imaging can be used for identiﬁcation
of subclinical coronary artery atherosclerosis to enhance
primary prevention of CAD, acute myocardial infarction,
and sudden cardiac death [6]. It is potentially able to detect
endothelial dysfunction and early, preclinical atherosclerotic
plaques vulnerable to rupture. Secondly it can be used at the
emergency department to help to decide whether to admit or
discharge a patient presenting with chest pain. And ﬁnally it
helps to stratify and follow patients who survive ACS for
choosing optimal treatment strategy [7].
Radionuclide imaging in primary prevention
The term vulnerable plaque has been introduced indicating
the high risk of plaque rupture or erosion, which subsequently
leads to ACS. The vulnerable plaque is, however, difﬁcult to
detect, and no biomarkers have been identiﬁed so far to allow
for early detection of the disease [8]. Sites of atherothrombosis
leading to ACS are associated with plaque rupture (60%),
plaque erosion (30%), calciﬁed nodules (2–7%) or very rarely
with isolated intra-plaque hemorrhage. Plaque rupture has
been initially considered predominantly mechanical, as it
occurs at sites of turbulent blood ﬂow. Very soon several
distinct biological features of rupturing plaques became
apparent. They are characterized by the presence of a thin
ﬁbrous cap, overlying a necrotic core which is heavily
inﬁltrated by macrophages (density up to 26%) and T
lymphocytes. While a morphological assessment of athero-
sclerotic plaques provides limited information in predicting
ACS, a functional assessment of inﬂammatory cells within the
plaque might better serve this scope. In particular, molecular
imaging of inﬂammatory cells within the plaque might help to
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irrespective of their severity and morphology [9].
Radionuclide imaging techniques including SPECT and PET
hold the potential for superior functional and molecular
atherosclerotic imaging for prediction of the risk of plaque
rupture. These techniques allow the study of changes at a
cellular and molecular level, and have been used for clinical
and research purposes to study myocardial perfusion, inner-
vation, angiogenesis, gene expression and stem cell labeling.
While such metabolic information is surplus to that provided
by MRI and MDCT, scintigraphic imaging techniques are
limited by relatively poor spatial and temporal resolution [10].
There are several targets that can be used to detect
vulnerable plaque.
Glucose is the most important substrate for metabolically
active cells, so its analog ﬂuorodeoxyglucose labeled with
Fluorine-18 (18F-FDG) was suggested to accumulate within the
atherosclerotic plaque in proportion to the degree of inﬂam-
mation and macrophage density. Rudd et al. demonstrated
that human carotid plaque inﬂammation can be imaged with
18F-FDG PET and that symptomatic plaques accumulate more
18FDG than asymptomatic lesions [11]. In addition, histological
examination of the excised symptomatic plaques in this study
revealed heavy macrophage inﬁltration. The assessment of
plaque inﬂammation by 18F-FDG in coronary arteries is more
challenging than that in carotid arteries for several reasons.
First, PET imaging has a limited spatial resolution (3–4 mm),
thus mandating the use of concomitant structural imaging
(either computed tomography or magnetic resonance imag-
ing) to guide localization of the 18F-FDG signal. Secondly,
coronary 18F-FDG imaging is challenged by its uptake in
adjacent myocardium, a hurdle that can be partially overcome
by the administration of FFA-enriched and low-carbohydrate
meals to suppress myocardial glucose metabolism [9]. Never-
theless Rogers et al. demonstrated increased 18F-FDG accu-
mulation both within the culprit lesion and in the ascending
aorta and left main coronary artery [12].
Calciﬁcation is another key feature of human atheroscle-
rosis. Coronary artery calcium scoring provides a surrogate
measure of the atherosclerotic burden and is a powerful
predictor of cardiovascular risk. Risk prediction can be
improved by examining the progression of coronary calciﬁca-
tion and by detecting spotty calciﬁcation [13]. Fluorine-18
sodium ﬂuoride (18F-NaF) is incorporated directly into exposed
hydroxyapatite crystal via an exchange mechanism with
hydroxyl groups. Therefore it detects novel areas of calciﬁca-
tion as its uptake reﬂects active calciﬁcation of atherosclerotic
plaque. Therefore, 18F-NaF seems to distinguish between
patients with dormant calciﬁc disease, established many
months or years previously, and subjects with metabolically
active disease where the calciﬁcation process is ongoing.
Importantly this distinction seems to be of clinical relevance,
with higher rates of anginal symptoms, prior MACE events,
and cardiovascular risk factor scores observed in those with
active disease. The spatial resolution of PET/CT is sufﬁcient to
localize 18F-NaF activity to speciﬁc coronary territories,
suggesting that 18F-NaF might be able to identify the presence
and location of recent plaque rupture. But still much research
needs to be done before the technique can become a viable
clinical option [14].Radionuclide imaging of patients with acute chest
pain in the intensive care unit
Clinical evaluation is fundamental to diagnosis, risk stratiﬁ-
cation and decision making in patients with chest pain and
suspected ACS. A detailed history remains the cornerstone of
the evaluation of patients with suspected ischemic coronary
syndromes. A diagnosis of ACS can be made based solely on
history if there is a compelling clinical scenario in a patient
with a moderate or high probability of ACS. However, the
majority of patients require further evaluation [3]. Risk
stratiﬁcation into categories deﬁned by the American College
of Cardiology/American Heart Association criteria should be
performed as indicated by the history, physical examination,
ECG, and cardiac injury markers. Low-risk patients for ACS are
those with no hemodynamic derangements or arrhythmias, a
normal or near-normal ECG, and negative initial cardiac injury
markers (mainly Troponin), which correlate with low likeli-
hood of ACS [15]. In such patients a conﬁrmatory test is
performed by any of several methods, from exercise treadmill
testing to cardiac imaging, depending on the speciﬁc features
of each patient. Negative results further minimize the
probability of ACS, thereby optimizing the safety and rationale
of discharging these patients.
Myocardial perfusion imaging (MPI) using SPECT has been
evaluated in several publications as an effective tool within a
chest pain work-up algorithm. Among patients presenting to
the emergency department with chest pain, nondiagnostic
ECG, and normal initial serum markers and enzymes,
myocardial perfusion SPECT has been shown to have a high
negative predictive value to rule out myocardial infarction
(99%) or future adverse cardiac events (97%) [6]. Moreover, rest
99mTc-sestamibi SPECT has been shown to improve medical
decision making by decreasing unnecessary hospitalizations
or prolonged observation periods in the emergency depart-
ment. In the context of acute chest pain (<6 h), its sensitivity
for detecting myocardial infarction is high (approximately
92%; range, 90–100%) [3]. However, the speciﬁcity of rest
imaging is suboptimal (67–78%) and has positive predictive
values of only 43–45%. One of the main reasons for this is that
hypoperfusion can be due to chronic ischemia, artifacts or
unstable angina without myocardial necrosis. Thus, abnormal
MPI is not speciﬁc for ongoing ACS. In a trial of 2475 patients
who presented with chest pain, randomization to a strategy
with acute rest MPI did not affect triage decisions in those
patients in whom the eventual diagnosis was myocardial
infarction or unstable angina; however, among those patients
without acute coronary ischemia (85% of the patients), MPI did
reduce the rate of admission [16]. The strength of resting MPI
lies with its high negative predictive value (approaching 100%)
and its value in short-term risk stratiﬁcation. Patients with a
normal rest MPI have a very low (<1%) 30-day cardiac event
rate, whereas patients with abnormal rest MPI may have a 10–
20% 30-day cardiac event rate. Also Peix et al. conﬁrmed that
patients presenting with acute chest pain and a low-to-
intermediate likelihood of coronary artery disease with a
normal rest MPI have a very low probability of cardiac events
during the ﬁrst year of follow-up. Coronary calcium score was
not helpful in risk-stratifying these patients [17]. However, the
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certainly no longer than 6 h following relief of pain. Thus, to
improve diagnosis and risk stratiﬁcation in patients with chest
pain and possible ACS, the use of rest myocardial perfusion
imaging has been assigned a class I, level A, indication by the
American College of Cardiology/American Heart Association/
American Society of Nuclear Cardiology (ACC/AHA/ASNC)
Radionuclide Imaging Guidelines for the assessment of
myocardial risk in possible ACS patients with a nondiagnostic
ECG and initial normal serum markers and enzymes [18].
A possible future approach for risk stratiﬁcation of patients
with suspected ACS involves imaging myocardial fatty acid
metabolism. Fatty acid imaging with radioiodine-labeled fatty
acid analogs such as 123I-b-methyliodopentadecanoic acid
(123I-BMIPP) using SPECT is still an investigational area for the
assessment of ischemic memory. After an ischemic episode,
abnormalities in fatty acid metabolism may persist long after
perfusion has returned to normal, a ﬁnding termed ‘‘ischemic
memory.’’ During this time period, the myocardium garners
the bulk of its energy from glucose metabolism [6]. Among
patients presenting to the emergency department with ACS
and no prior myocardial infarction, the clinical utility of 123I-
BMIPP for identifying myocardial ischemia was examined in
111 consecutive patients [19]. All patients were admitted and
underwent a rest myocardial perfusion SPECT study within
24 h of chest pain, rest 123I-BMIPP metabolic imaging within
48 h after the perfusion SPECT, and coronary angiography
within 1–4 days of admission. 123I-BMIPP defects at rest were
present in 74% of patients with documented coronary artery
stenosis or vasospasm (on ergonovine provocation), whereas
only 38% of patients showed myocardial perfusion defects at
rest (P < 0.001). Both 123I-BMIPP and perfusion studies wereFig. 1 – Reversible perfusion defect in the area of an anterior wall 
the left anterior descending coronary artery). Upper row – stress p
left, vertical long axis slice in the middle and horizontal long axis
SPECT technique.normal in nearly 90% of patients without coronary artery
stenosis or vasospasm.
Conti et al. evaluated the implementation of exercise MPI in
the early triage of 306 patients with suspected ACS and normal
ﬁndings on an initial workup [20]. The sensitivity and speciﬁcity
to predict signiﬁcant CAD or adverse events within 6 months
were 94% (45/48) and 77% (198/258), respectively. A large
observational study of 805 patients with low to intermediate
risk of CAD compared the diagnostic performance of rest MPI
with stress MPI. In that study, investigators evaluated the
sensitivity and speciﬁcity for diagnosing the following events
within 30 days of MPI: AMI, revascularization, stenosis of more
than 70% on invasive CAG not amenable to revascularization,
life-threatening complication, or cardiac death. The sensitivity
and speciﬁcity of rest MPI, 71% (109/153) and 73% (476/652),
respectively, were signiﬁcantly lower than the sensitivity and
speciﬁcity of stress MPI, 97% (148/153) and 88% (574/652) [21].
Limitation
Physicians should be aware of possible false negative results of
rest images in patients with subsided chest pain or balanced
ischemia caused by a three-vessel disease. AMI should be
excluded before performing stress MPI by measuring serial
cardiac markers or performing rest imaging. This need to
exclude AMI results in a longer diagnostic workup [1].
Radionuclide imaging in patients surviving ACS
Among patients with acute coronary syndromes, a major
beneﬁt results from the utilization of potent antithromboticand a septum of the left ventricle (probably in the territory of
erfusion, lower row – rest perfusion. Short axis slice on the
 slice on the right. Images performed with 99mTc MIBI using
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Yet, in real life, they still present a 10–15% risk of death at 6
months and an even higher risk of re-infarction and heart
failure [9]. It is well established that myocardial function and
perfusion represent important determinants of long-term
outcome. In this regard, radionuclide imaging is able to
evaluate a degree of the left ventricular dysfunction as well as
to assess the volume of an infarcted myocardium, jeopardized
myocardium by detecting a residual ischemia, and the volume
of a viable myocardium [22,23].
Analysis of LV function on gated studies correlated well
with MRI in a meta-analysis of nine studies. However, the
margin of error was higher in women with smaller left
ventricular volumes, with dilated cardiomyopathy and in the
presence of global subendocardial perfusion defects [2].
SPECT imaging has been available since the 1970s and has
given us a large body of evidence conﬁrming its diagnostic and
prognostic value. The commonly used radiopharmaceuticals
are thallium-201 chloride and technetium-based agents such
as 99mTc sestamibi and 99mTc tetrofosmin. Reversible defect,
which means reduced tracer uptake on the stress acquisition
which disappears on the rest acquisition (Fig. 1), is typical for
ischemia (de facto exhausted coronary ﬂow reserve (CFR)). A
ﬁxed defect, i.e., a defect present on both stress and rest
acquisitions (Fig. 2), is suggestive of a scar or hibernating
myocardium provided attenuation artifacts are ruled out.
Applying state-of-the-art technology and radiopharmaceuti-
cals, the sensitivity and speciﬁcity for detecting occlusive CAD
with gated SPECT are now in the range of 91% and 72%,
respectively [6]. PET imparts a higher speciﬁcity than SPECT,
around 90%, which is most likely a consequence of its superior
attenuation correction, increased count-density images, and
superior spatial resolution. In a meta-analysis of 19 studies,
PET had a sensitivity of 92% and a speciﬁcity of 85% forFig. 2 – Fixed perfusion defect in the area of inferior wall of the 
artery). Arrangement of the images as in Fig. 1. Images performdiagnosing signiﬁcant CAD (deﬁned as >50% luminal narrow-
ing) [24]. Moreover, PET has the advantage of being able to
measure myocardial blood ﬂow in absolute units, which is
important in the assessment of the distal coronary microcir-
culation [25,26]. Dynamic PET imaging, with the utilization of
appropriate tracers and kinetic models, allows regional
measurement of absolute MBF, expressed as milliliters per
minute per gram. Moreover, the measurement of MBF at rest
and during maximal hyperemia, obtained by systemic
infusion of adenosine or dypiridamole, allows to quantify
CFR, deﬁned as the ratio of MBF at maximal coronary
vasodilation to that at rest. CFR represents an integrated
measure of blood ﬂow through all coronary arterial bed since
an abnormal CFR can be either related to a narrowing of an
epicardial coronary artery or reﬂect coronary microvascular
dysfunction [27,28]. A false negative study using SPECT may
be a feature of three-vessel and left main stem disease
because SPECT assesses relative perfusion. Normal perfusion
is seen in up to 13–15% of patients with left main stem disease
on account of balanced ischemia in multivessel disease [29].
False positive tests due to attenuation artifacts lower the
speciﬁcity. For example, an elevated diaphragm results in an
apparent ﬁxed defect in the inferior wall in men, and breast
artifact gives rise to an apparent defect in the anterior wall in
women. Implementing gated studies, attenuation correction
algorithm and prone imaging help improve the speciﬁcity by
reducing the number of equivocal scans in such cases.
Referral bias, introduced by the fact that only patients with
a positive test will undergo an invasive angiogram, also
falsely lowers the speciﬁcity.
Viability assessment is usually based on demonstration of
the integrity of the cell membrane and the presence of residual
perfusion following an injection of a perfusion tracer [2,30].
Pooled meta-analysis of thallium and tetrofosmin studiesleft ventricle (probably in the territory of the right coronary
ed with 99mTc MIBI using SPECT technique.
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49–69% for prediction of regional functional recovery after
revascularization. This suggests that it has a good negative
predictive value. The poor positive predictive value is due to
the poor spatial resolution of the technique. Subendocardial
infarcts are beyond the spatial resolution of SPECT and are
likely to be missed, leading to overestimation of viability.
18F-FDG is the most utilized metabolic tracer to study
carbohydrate metabolism and, since cellular glucose uptake is
proportional to its consumption, the measurement of 18F-FDG
uptake, expressed as micromoles per minute per gram,
provides an indirect quantiﬁcation of its effective utilization
[9]. Under ischemic conditions, the reduction of oxygen supply
is associated with a decrease in FFA oxidative metabolism and
a switch to preferential glucose utilization for myocardial
energy production. However, due to high inter-individual
variability and low normal glucose cardiac utilization, accurate
quantiﬁcation of myocardial 18F-FDG uptake requires steady
state and standardized metabolic conditions that can be
achieved by a hyperinsulinemic-euglycemic clamp. This
protocol is based on concomitant administration of intrave-
nous glucose load and insulin, leading to a switch of
myocardium metabolism to glucose and maximizing 18F-
FDG uptake, thus optimizing image quality. During a hyper-
insulinemic-euglycemic clamp, absolute regional myocardial
18F-FDG uptake can be reliably quantiﬁed.
In the setting of chronic CAD, the concomitant assessment
of myocardial perfusion and metabolism allows an accurateFig. 3 – Perfusion–metabolism match: scar tissue in the area of i
artery). Upper row – perfusion (99mTc MIBI), lower row – glucose
Fig. 1. Images performed with simultaneous acquisition using Sdifferentiation between hibernated and infarcted myocardium
in regions characterized by severe contractile impairment. In
the presence of ‘‘perfusion–metabolism match’’ (Fig. 3), a
severely reduced or absent glucose metabolism indicates scar
tissue unlikely to recover upon reperfusion. Conversely, in the
presence of ‘‘perfusion–metabolism mismatch’’ (Fig. 4), pre-
served or even enhanced glucose metabolism indicates
hibernating myocardium susceptible of functional recovery
upon reperfusion. The applicability of a perfusion/metabolism
match/mismatch model, however, is controversial in the sub-
acute phase of STEMI, due to the complex mechanisms of
myocardial response to necrosis involving coronary microcir-
culation dysfunction and tissue inﬂammation [9]. Because of
these complexities, a ‘‘mismatch pattern’’ in the sub-acute
phase of STEMI can be caused by epicardial artery occlusion,
coronary microvascular obstruction, inﬂammatory cell activa-
tion, or a combination of these mechanisms. So the study of
myocardial perfusion and metabolism by PET in the sub-acute
phase of STEMI has allowed us to considerably improve our
knowledge of its pathophysiology, but its clinical usefulness is
limited by the complex interplay between epicardial artery
obstruction, coronary microvascular obstruction, and inﬂam-
matory cell activation. On the other hand the assessment of
myocardial perfusion using ammonia labeled with 13N could
predict functional recovery after an AMI. Lancellotti et al. have
demonstrated that regions with an ammonia uptake of >63%
of maximal segment uptake as compared with that observed
in normal subjects showed a signiﬁcant improvement in wallnferior wall (probably in the territory of the right coronary
 metabolism (18F-FDG). Arrangement of the images as in
PECT technique.
Fig. 4 – Perfusion–metabolism mismatch: viable hibernating myocardium in the area of the apex and the surrounding tissue
of the left ventricle. Arrangement and imaging as in Fig. 3.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 3 5 4 – e 3 6 1e360motion with a predictive value of 86%, while a limited accuracy
was found for segments with moderately (between 63% and
50%) and severely (<50%) reduced ﬂow [31].
Conclusion
There are no signiﬁcant differences among radionuclide imag-
ing, CT angiography and echocardiography for the detection of
both ACS andCAD with or without follow-up [1]. It is important to
keep in mind that the optimal imaging strategyisdetermined not
only by the diagnostic performance of a modality but also by local
practice, expertise with imaging techniques, medical facilities,
and individual patient characteristics. Given the absence of large
differences in diagnostic performance, these practical aspects
may be even more important.
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